Shirkadda dawooyinka ee Denmark ee LEO Pharma oo dib u dhigtay ku biirista suuqa saamiyada
Published
Shirkadda dawooyinka ee Denmark ee LEO Pharma waxay hadda joojisay qorshaheeda ah inay ku biirto suuqa saamiyada (IPO). Shirkaddu ma gelayso suuqa saamiyada wakhti dambe. Warbixinnada ayaa lagu sheegay in sannadka 2026 aanay jiri doonin wax ku biirid suuqa saamiyada.
LEO Pharma waa mid ka mid ah shirkadaha dawooyinka ee waaweyn ee Denmark. Shirkaddu waxay soo saartaa oo iibisaa dawooyin, gaar ahaan kuwa cudurrada maqaarka. Ku biirista suuqa saamiyada waxay ka dhigan tahay in shirkaddu iibiso saamiyo dadweynaha. Tani inta badan waxay siisaa lacag, laakiin sidoo kale waxay ku qasbaysaa shirkadda inay furto shuquldhaqankeeda maalgashatada, suuquna si dhow ayuu u daba socdaa.
Shirkadaha badanaa way dib u dhigaan ku biirista suuqa marka xaaladda suuqu aanay hubin. Maalgashatadu way taxaddaraan karaan, qiimaha shirkaddu waxa laga yaabaa inuu hooseeyo intii shirkaddu rajaynayso. Weli lama hayo macluumaad faahfaahsan oo ku saabsan sababaha ay LEO Pharma u sheegtay go'aankan.
Akhristayaasha Iswiidhish, warkan wuxuu muhiim u yahay sababtoo ah wuxuu khuseeyaa shirkad dawooyin oo Nordic ah, wuxuuna muujinayaa sida xaaladda suuqa lacagta ay u saameyn karto shirkadaha waaweyn ee gobolka. Weli ma cadda goorta LEO Pharma mar dambe dib u bilaabi karto qorshayaasheeda. Shirkaddu ilaa hadda waxay sheegtay oo keliya in sannadkan aysan ku biirin doonin suuqa saamiyada.
Sources: lifesciencefocus.com
More Sweden news
- Slow start for Sverige-id: authorities can get up to nine months' exemption
- Marcus Bergman leaves Sweden after more than 400 matches in Hockeyallsvenskan
- Trust in Sweden could affect the country's defence capability
- New rabies vaccine from Sanofi approved in the EU
- This is what the Swedish royals are really like, according to an expert
- Musikhjälpen 2026: The first prize is tickets to a Premier League match
- Business leaders impatient with AI: small progress is no longer enough
- Sweden expected to attract twice as much venture capital this year